Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy BioNTech stock | $101.59

Own BioNTech stock in just a few minutes.

Fact checked

BioNTech SE is a German biotechnology company headquartered in Mainz, Germany. Alongside Pfizer, it developed a COVID-19 vaccine now approved by the U.S. Food and Drug Administration for emergency use. Investors can back the company by purchasing American Depositary Receipts (ADRs) on the Nasdaq under the ticker symbol BNTX.

Latest updates

Friday, December 11: The U.S. Food and Drug Administration cleared the Covid-19 vaccine developed by Pfizer and BioNTech for emergency use, with millions of doses expected to go out in the next few days.

Tuesday, December 8: Britain began vaccinations using the drug developed by Pfizer and BioNTech.

Wednesday, December 2: The UK becomes the first country to approve the Pfizer-BioNTech vaccine for emergency use, with vaccine distribution expected for the following week.

Tuesday, December 1: Advisors to the Center for Disease Control recommended that the first doses of any COVID-19 vaccine should be given to health-care workers and workers in nursing homes and other care facilities, according to news reports.

Wednesday, November 18: Pfizer releases final data from its Phase 3 study and amends the efficacy rate of its vaccine, stating its vaccine is 95% effective in preventing COVID-19.

Monday, November 9: Pfizer announces the two-dose vaccine it’s developing with BioNTech is over 90% effective in preventing COVID-19.

How to buy shares in BioNTech

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for BioNTech. Find the stock by name or ticker symbol: BNTX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until BioNTech reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$101.59, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of BioNTech, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of BioNTech. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Pfizer and BioNTech’s COVID-19 vaccine

On Nov. 9, Pfizer released a statement based on an early analysis of the two-dose COVID-19 vaccine it’s developing with BioNTech. The company says its vaccine is 95% effective in preventing COVID-19 in patients with no evidence of prior infection.

That said, the protection rate of the vaccine could change by the time its study ends. This is encouraging data — but it’s early data. And it hasn’t been peer-reviewed.

On December 2, the UK became the first country to officially approve the Pfizer-BioNTech COVID-19 vaccine for emergency use. The first round of vaccines is expected to roll out in the following weeks to front-line medical workers and residents of long-term care homes.

Pfizer is also preparing an application to the U.S. Food and Drug Administration (FDA) for emergency-use approval. Canadian Prime Minister Justin Trudeau has placed an order for 20 million doses of the vaccine, stating the vaccine will be deployed as soon as it’s approved by Health Canada.

In response to Pfizer’s announcement, the S&P 500 rose 2.8%, the Dow Jones Industrial Average surged by 1,092 points, Pfizer’s stock saw a 9% increase and BioNTech’s stock saw a 14% increase.

Pfizer expects to produce over 50 million doses in 2020 and up to 1.3 billion doses in 2021. A panel advising the Centers for Disease Control recommended December 1 that the first doses go to health-care workers and the staffs of nursing homes and care facilities.

How has coronavirus impacted BioNTech's share price?

Since the stock market crash in March caused by coronavirus, BioNTech's share price has had significant positive movement.

Its last close price was USD$101.59, which is 68.16% up on its pre-crash value of USD$32.35 and 262.82% up on the lowest point reached during the March crash when the shares fell as low as USD$28.

If you had bought USD$1,000 worth of BioNTech shares at the start of February 2020, those shares would have been worth USD$1,695.28 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$3,356.53.

BioNTech share price

Use our graph to track the performance of BNTX stocks over time.

BioNTech shares at a glance

Information last updated 2021-01-15.
OpenUSD$104.25
HighUSD$104.99
LowUSD$97.25
CloseUSD$101.59
Previous closeUSD$105.85
Change USD$-4.26
Change % -4.025%
Volume 3,151,568
Information last updated 2021-01-12.
52-week rangeUSD$28 - USD$131
50-day moving average USD$106.1594
200-day moving average USD$84.9323
Wall St. target priceUSD$116.76
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.5631

Buy BioNTech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy BioNTech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BioNTech price performance over time

Historical closes compared with the close of $101.59 from 2020-10-19

1 week (2021-01-11) -6.71%
1 month (2020-12-18) -2.54%
3 months (2020-10-16) 7.97%
6 months (2020-07-17) 19.17%
1 year (2020-01-17) 206.18%
2 years (2019-01-14) N/A
3 years (2018-01-14) N/A
5 years (2016-01-14) N/A

BioNTech financials

Gross profit TTM USD$91.2 million
Return on assets TTM -22.13%
Return on equity TTM -61%
Profit margin -248.64%
Book value N/A
Market capitalisation USD$26.2 billion

TTM: trailing 12 months

Shorting BioNTech shares

There are currently 6.3 million BioNTech shares held short by investors – that's known as BioNTech's "short interest". This figure is 9.8% down from 7.0 million last month.

There are a few different ways that this level of interest in shorting BioNTech shares can be evaluated.

BioNTech's "short interest ratio" (SIR)

BioNTech's "short interest ratio" (SIR) is the quantity of BioNTech shares currently shorted divided by the average quantity of BioNTech shares traded daily (recently around 5.8 million). BioNTech's SIR currently stands at 1.09. In other words for every 100,000 BioNTech shares traded daily on the market, roughly 1090 shares are currently held short.

However BioNTech's short interest can also be evaluated against the total number of BioNTech shares, or, against the total number of tradable BioNTech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioNTech's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 BioNTech shares in existence, roughly 30 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable BioNTech shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioNTech.

Find out more about how you can short BioNTech stock.

BioNTech share dividends

We're not expecting BioNTech to pay a dividend over the next 12 months.

BioNTech overview

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer. It also develops neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I/II clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Eli Lilly and Company; Bayer AG; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc.; and InstaDeep Ltd. The company was founded in 2008 and is headquartered in Mainz, Germany.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site